Clinical Trials Browser

Phase 1/2 × necitumumab × Thoracic × Clear all

NCT04285671 2026-03-10

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01763788 2019-10-25

A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

192 enrolled 24 charts

Squamous Non-small Cell Lung Cancer